Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 101–200 of 1,000
Postorino, V., Sharp, W. G., McCracken, C. E., Bearss, K., Burrell, T. L., Evans, A. N., & Scahill, L. (2017) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-017-0237-2 · Cited by 210
Self-citationLounds, J., Seltzer, M. M., Greenberg, J. S., & Shattuck, P. T. (2007) · American Journal on Mental Retardation · doi:10.1352/0895-8017(2007)112[401:taciaa]2.0.co;2 · Cited by 210
Antipsychotics in the treatment of autism
Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32483 · Cited by 210
Self-citationEstrogens Suppress a Behavioral Phenotype in Zebrafish Mutants of the Autism Risk Gene, CNTNAP2
Hoffman, E. J., Turner, K. J., Fernandez, J. M., Cifuentes, D., Ghosh, M., Ijaz, S., Jain, R. A., Kubo, F., Bill, B. R., Baier, H., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.12.039 · Cited by 209
“Autism spectrum disorders (ASDs) are a group of neurodevelopmental syndromes characterized by deficits in social interaction and communication as well as repetitive behaviors and restricted interests (American Psychiatric Association, 2013).”
InfluentialTroost, P. W., Lahuis, B. E., Steenhuis, M.-P., Ketelaars, C. E. J., Buitelaar, J. K., van Engeland, H., Scahill, L., Minderaa, R. B., & Hoekstra, P. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000177055.11229.76 · Cited by 203
Self-citationPsychiatric Hospitalization Among Children with Autism Spectrum Disorders
Mandell, D. S. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0481-2 · Cited by 197
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010055 · Cited by 201
Self-citationRendleman, R., & Walkup, J. T. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 196
Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders
Hallett, V., Lecavalier, L., Sukhodolsky, D. G., Cipriano, N., Aman, M. G., McCracken, J. T., McDougle, C. J., Tierney, E., King, B. H., Hollander, E., et al. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1775-1 · Cited by 193
Self-citationRisperidone for autism spectrum disorder
Jesner, O. S., Aref-Adib, M., & Coren, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005040.pub2 · Cited by 190
Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J., & The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group (2011) · Paediatrics & Child Health · doi:10.1093/pch/16.9.581 · Cited by 192
An update on pharmacotherapy of autism spectrum disorder in children and adolescents
Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1458706 · Cited by 176
“…irritability (agitation, anger outbursts, and self-injurious behaviour), stereotypy, and hyperactivity (Ichikawa et al., 2016; Kent et al., 2013; Marcus et al., 2009; McCracken et al., 2002; McDougle et al., 2005; Owen et al., 2009; Pandina, Bossie, Youssef, Zhu, & Dunbar, 2007; Shea et al., 2004).”
BackgroundMethodInfluentialGeller, B., Badner, J. A., Tillman, R., Christian, S. L., Bolhofner, K., & Cook, E. H. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1698 · Cited by 189
Bearss, K., Burrell, T. L., Challa, S. A., Postorino, V., Gillespie, S. E., Crooks, C., & Scahill, L. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3363-2 · Cited by 185
Self-citationAttention-deficit/hyperactivity disorder in the context of autism spectrum disorders
Murray, M. J. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0145-3 · Cited by 185
Trends in Prescribing of Antipsychotic Medications for US Children
Cooper, W. O., Arbogast, P. G., Ding, H., Hickson, G. B., Fuchs, D. C., & Ray, W. A. (2006) · Ambulatory Pediatrics · doi:10.1016/j.ambp.2005.11.002 · Cited by 185
Tics and Tourette syndrome in autism spectrum disorders
Canitano, R., & Vivanti, G. (2007) · Autism · doi:10.1177/1362361307070992 · Cited by 178
Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9181-6 · Cited by 183
“VAS-Anxiety and Disruptive Behaviors This methodology has been utilized in autism [18, 22].”
BackgroundMethodInfluentialProdromal interventions for schizophrenia vulnerability: the risks of being “at risk”
Corcoran, C., Malaspina, D., & Hercher, L. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.021 · Cited by 183
“…tic disorders (Gilbert et al., 2004; Scahill et al., 2003), the psychotic symptoms of schizophrenia (Zalsman et al., 2003), and disruptive behavior in children with low IQ (Turgay et al., 2002) or with pervasive developmental disorders, such as autism (Masi et al., 2003; McCracken et al., 2002).”
BackgroundTrends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents
Patel, N. C., Crismon, M. L., Hoagwood, K., Johnsrud, M. T., Rascati, K. L., Wilson, J. P., & Jensen, P. S. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157543.74509.c8 · Cited by 186
What is Known About Autism: Genes, Brain, and Behavior
Santangelo, S. L., & Tsatsanis, K. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505020-00001 · Cited by 182
Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., Hall, S., Ermer, D. J., Tsai, L. Y., Schroeder, S. R., et al. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.682 · Cited by 180
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder
Bartzokis, G., Lu, P. H., Turner, J., Mintz, J., & Saunders, C. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.039 · Cited by 182
Focal brain inflammation and autism
Theoharides, T. C., Asadi, S., & Patel, A. B. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-46 · Cited by 178
“Such drugs include antipsychotic medications [89], the newer atypical compounds [90,91] risperidone [92,93] and aripiprazole [94] for obsessive-compulsive symptoms, aggression and self-injury, as well as methylphenidate for hyperactivity [95].”
BackgroundTreatment of Autism Spectrum Disorder in Children and Adolescents
DeFilippis, M., & Wagner, K. D. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4346 · Cited by 177
Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders
SCAHILL, L., MCDOUGLE, C. J., WILLIAMS, S. K., DIMITROPOULOS, A., AMAN, M. G., MCCRACKEN, J. T., TIERNEY, E., ARNOLD, L. E., CRONIN, P., GRADOS, M., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220854.79144.e7 · Cited by 177
Self-citationSansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., Berry-Kravis, E., Lachiewicz, A., Brown, E. C., & Hessl, D. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1370-2 · Cited by 176
Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder
Lecavalier, L., Wood, J. J., Halladay, A. K., Jones, N. E., Aman, M. G., Cook, E. H., Handen, B. L., King, B. H., Pearson, D. A., Hallett, V., et al. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1974-9 · Cited by 174
Self-citationFragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
“Some of the most problematic and difficult symptoms for parents to handle in their children with FXS and autism are behavioral problems, including self-injurious behaviors, aggression, and irritability.(142) Risperidone, an atypical antipsychotic, has recently been approved by the”
BackgroundAntipsychotic Medication Prescribing Trends in Children and Adolescents
Harrison, J. N., Cluxton-Keller, F., & Gross, D. (2012) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2011.10.009 · Cited by 175
“Cases of drooling also have been reported (McCracken et al., 2002).”
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., Arnold, L. E., Martin, A., Katsovich, L., Posey, D. J., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.032 · Cited by 176
Self-citationPractice Parameter on the Use of Psychotropic Medication in Children and Adolescents
Walkup, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181ae0a08 · Cited by 173
Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., Dziura, J., Butter, E., Swiezy, N. G., Arnold, L. E., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.11.010 · Cited by 174
Self-citationGreen, R. M., Travers, A. M., Howe, Y., & McDougle, C. J. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1006-3 · Cited by 174
Self-citationLv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-196 · Cited by 174
Medication Patterns in Patients with Autism: Temporal, Regional, and Demographic Influences
Aman, M. G., Lam, K. S. L., & Van Bourgondien, M. E. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.116 · Cited by 174
Self-citationLuby, J., Mrakotsky, C., Stalets, M. M., Belden, A., Heffelfinger, A., Williams, M., & Spitznagel, E. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.575 · Cited by 177
Autism spectrum disorders: an overview on diagnosis and treatment
Brentani, H., Paula, C. S. D., Bordini, D., Rolim, D., Sato, F., Portolese, J., Pacifico, M. C., & McCracken, J. T. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-s104 · Cited by 166
Self-citationNovel treatments for autistic spectrum disorders
Levy, S. E., & Hyman, S. L. (2005) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20062 · Cited by 171
“An example is the Research Units in Pediatric Psychopharmacology (RUPP) trial demonstrating the efficacy of risperidone for treatment of irritability and aggression [McCracken et al., 2002].”
MethodTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics
Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_5003 · Cited by 170
“Risperidone, which modulates dopamine and serotonin systems, had a significant effect on stereotyped behavior in children with ASD (McCracken et al. 2002; McDougle et al. 2005; Chavez et al. 2006), although this was not seen in all studies (Ghaeli et al.”
BackgroundAcute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman, M. G., Arnold, M. D., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., et al. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.869 · Cited by 170
Self-citationSerotonin and dopamine transporter binding in children with autism determined by SPECT
Makkonen, I., Riikonen, R., Kokki, H., Airaksinen, M. M., & Kuikka, J. T. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03027.x · Cited by 169
“Dopamine receptor antagonists such as risperidone have been shown to alleviate some behavioural features in autism.(11) However, cerebrospinal fluid (CSF) homovanillic acid concentration has not indicated clear abnormalities of brain dopamine metabolism in children with autism.”
BackgroundMazefsky, C. A., Yu, L., White, S. W., Siegel, M., & Pilkonis, P. A. (2018) · Autism Research · doi:10.1002/aur.1947 · Cited by 169
New Users of Antipsychotic Medications Among Children Enrolled in TennCare
Cooper, W. O., Hickson, G. B., Fuchs, C., Arbogast, P. G., & Ray, W. A. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.8.753 · Cited by 167
Aman, M. G., Lam, K. S. L., & Collier-Crespin, A. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025883612879 · Cited by 163
Self-citationFindling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & The Risperidone Disruptive Behavior Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.677 · Cited by 161
Self-citationCarr, E. G., & Horner, R. H. (2007) · Journal of Positive Behavior Interventions · doi:10.1177/10983007070090010201 · Cited by 214
JENSEN, P. S., YOUNGSTROM, E. A., STEINER, H., FINDLING, R. L., MEYER, R. E., MALONE, R. P., CARLSON, G. A., COCCARO, E. F., AMAN, M. G., BLAIR, J., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31802f1454 · Cited by 159
Self-citationGhanizadeh, A., & Moghimi-Sarani, E. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-196 · Cited by 152
“2) [39].”
Kent, J. M., Kushner, S., Ning, X., Karcher, K., Ness, S., Aman, M., Singh, J., & Hough, D. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1723-5 · Cited by 159
“25 mg/ day was selected based on prior studies (McCracken et al. 2002; Shea et al. 2004).”
BackgroundMethodResultInfluentialSelf-citationUpdated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry-Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 157
Frye, R. E. (2018) · CNS Drugs · doi:10.1007/s40263-018-0556-y · Cited by 151
“Antipsychotic trials have targeted highly irritable individuals with ASD because their primary outcome measure was ABC irritability [128].”
BackgroundResultA pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder
Bent, S., Bertoglio, K., Ashwood, P., Bostrom, A., & Hendren, R. L. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1078-8 · Cited by 156
“A 25% reduction in the baseline scores in the ABC has previously been used to define a ‘‘positive response’’ to therapy in autism (McCracken et al. 2002).”
MethodBerry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., Decle, P., Potanos, K., Cook, E., Salt, J., et al. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.525 · Cited by 155
Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., & Jacob, S. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.049 · Cited by 155
“Specifically, drugs that were developed for other disorders with potentially overlapping phenotypes were tested in ASD, assuming that phenotypic spectra would be associated with neurobiologic spectra.”
MethodInfluentialOutcome Measures for Clinical Trials in Fragile X Syndrome
Berry‐Kravis, E., Hessl, D. R., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A. C., & Urv, T. K. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31829d1f20 · Cited by 165
Capone, G. T., Grados, M. A., Kaufmann, W. E., Bernad‐Ripoll, S., & Jewell, A. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30622 · Cited by 154
“Additionally, the ABC has proven useful for measuring target symptoms associated with ASD in several clinical drug trials (Scahill and RUPP 2002), (Aman, Novotny et al.”
MethodSelf-citationFragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 154
“sponse rates in the range of 12–14% [138, 139].”
BackgroundAutism interventions: a critical update
Francis, K. (2005) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162205000952 · Cited by 144
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
“Although there is no association An 88-week, open-label study with 10 children and ending doses ranging from 300–800 mg/day showed minimal untoward events and a favorable long-term safety and tolerability (McConville et al. 2003”
Self-citationPsychopharmacology in fragile X syndrome—Present and future
Berry‐Kravis, E., & Potanos, K. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20007 · Cited by 151
Conner, C. M., White, S. W., Beck, K. B., Golt, J., Smith, I. C., & Mazefsky, C. A. (2019) · Autism · doi:10.1177/1362361318810709 · Cited by 150
“The CGI-I has been used in many studies over the past three decades, including clinical trials of treatments for ASD (e.g. McCracken et al., 2002).”
MethodValidity of the Autism Diagnostic Interview-Revised
Lecavalier, L., Aman, M. G., Scahill, L., McDougle, C. J., McCracken, J. T., Vitiello, B., Tierney, E., Arnold, L. E., Ghuman, J. K., Loftin, R. L., et al. (2006) · American Journal on Mental Retardation · doi:10.1352/0895-8017(2006)111[199:votadi]2.0.co;2 · Cited by 151
Self-citationPharmacological therapies for autism spectrum disorder: a review.
(2015) · PubMed Central · Cited by 150
Page, D. T., Kuti, O. J., Prestia, C., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804428106 · Cited by 149
“It is interesting to note that 3 drugs that have been reported as alleviating symptoms of autism—the atypical antipsychotics risperidone (37) and olanzapine (38) and the antidepressant fluoxetine (39)— all have antagonistic effects on the 5-HT2c receptor, in addition to well-known effects targeting other members of th…”
BackgroundRandomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., Onelio, L., Pine, D. S., & Leibenluft, E. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.044 · Cited by 148
“One of two double-blind, placebo-controlled RCTs showed significant global improvement (without specific reference to irritability) in youths with either BD or high risk for BD and secondary substance abuse (Geller et al. 1998a).”
Perihan, C., Burke, M., Bowman-Perrott, L., Bicer, A., Gallup, J., Thompson, J., & Sallese, M. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-03949-7 · Cited by 148
Almandil, N. B., Liu, Y., Murray, M. L., Besag, F., Aitchison, K. J., & Wong, I. C. K. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0016-6 · Cited by 156
Koenig, K. P., Buckley-Reen, A., & Garg, S. (2012) · The American Journal of Occupational Therapy · doi:10.5014/ajot.2012.004390 · Cited by 145
“The most recent figure released by the CDC is that 1 in 88 children are now diagnosed with ASD (CDC, 2012), a prevalence that has implications for occupational therapy practitioners in all practice settings.”
InfluentialSelf-citationIrritability in pediatric mania and other childhood psychopathology
LEIBENLUFT, E., BLAIR, R. J. R., CHARNEY, D. S., & PINE, D. S. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1301.022 · Cited by 145
Haas, M., Unis, A. S., Armenteros, J. L., Copenhaver, M. D., Quiroz, J. A., & Kushner, S. F. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0144 · Cited by 148
“…in adult schizophrenia subjects treated with risperidone and in other studies of risperidone treatment in children and adolescents with autism, pervasive developmental disorders, or disruptive behavior disorders (Aman et al. 2002; McCracken et al. 2002; Snyder et al. 2002; Reyes et al. 2006a).”
Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S.-Y., Aman, M. G., McDougle, C. J., Scahill, L., Tierney, E., Eugene Arnold, L., Vitiello, B., et al. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0636-9 · Cited by 144
Self-citationEack, S. M., Bahorik, A. L., McKnight, S. A. F., Hogarty, S. S., Greenwald, D. P., Newhill, C. E., Phillips, M. L., Keshavan, M. S., & Minshew, N. J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.013 · Cited by 145
A Comparison of Risperidone-Induced Weight Gain Across the Age Span
Safer, D. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000130558.86125.5b · Cited by 144
Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0234-7 · Cited by 144
Siegel, M. S., & Beaulieu, A. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1399-2 · Cited by 170
Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., Soorya, L., & Hollander, E. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000224787.13782.0f · Cited by 142
Miral, S., Gencer, Ö., İnal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dırık, E. (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-0620-5 · Cited by 156
“Results of double-blind placebo controlled trials in children [28, 37] and adults [30] suggest that risperidone is effective and well tolerated in treating behavioral symptoms of autism or PDD.”
Kane, M. J., Angoa-Peréz, M., Briggs, D. I., Sykes, C. E., Francescutti, D. M., Rosenberg, D. R., & Kuhn, D. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048975 · Cited by 143
“While TPH22/2 mice are very aggressive, we do not view this as a confounding behavior but one that is also characteristic of ASDs [71,82,83], albeit not a core behavioral trait.”
BackgroundExploring sleep quality of young children with autism spectrum disorder and disruptive behaviors
Johnson, C. R., Smith, T., DeMand, A., Lecavalier, L., Evans, V., Gurka, M., Swiezy, N., Bearss, K., & Scahill, L. (2018) · Sleep Medicine · doi:10.1016/j.sleep.2018.01.008 · Cited by 138
Self-citationBearss, K. E., Johnson, C. R., Handen, B. L., Smith, T. H., & Scahill, L. D. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1624-7 · Cited by 174
Self-citationPersico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., Vitiello, B., & Arango, C. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110326 · Cited by 155
Self-citationDoyle, C. A., & McDougle, C. J. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.3/cdoyle · Cited by 136
“One of the multisite, double-blind, placebo-controlled trials that led to the FDA approval of risperidone for the treatment of irritability in children and adolescents with autism revealed a 69% response rate with a 57% decrease in irritability as measured by the ABC Irritability subscale.(69) Similar results were obs…”
ResultSelf-citationMontes, G., & Halterman, J. S. (2007) · Ambulatory Pediatrics · doi:10.1016/j.ambp.2007.02.003 · Cited by 136
Murray, M. L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D. G. M., Asherson, P. J., Eklund, H., & Wong, I. C. K. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3140-7 · Cited by 134
Development of a parent training program for children with pervasive developmental disorders
Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., Sukhodolsky, D. G., Williams, S., Swiezy, N. A., Arnold, L. E., Aman, M. G., et al. (2007) · Behavioral Interventions · doi:10.1002/bin.237 · Cited by 135
Self-citationPringsheim, T. M., Lam, D., Ching, H., & Patten, S. B. (2011) · Drug Safety · doi:10.2165/11592020-000000000-00000 · Cited by 151
Evidence-Based Treatments in Child and Adolescent Psychiatry: An Inventory
McClellan, J., & WERRY, J. S. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00005 · Cited by 149
An exploration of concomitant psychiatric disorders in children with autism spectrum disorder
Lecavalier, L., McCracken, C. E., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Smith, T., Johnson, C., King, B., Handen, B., et al. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.10.012 · Cited by 127
Self-citationWeight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data
Martin, A., Scahill, L., Anderson, G. M., Aman, M., Arnold, L. E., McCracken, J., McDougle, C. J., Tierney, E., Chuang, S., Vitiello, B., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1125 · Cited by 133
Self-citationThe Psychopharmacology of Aggressive Behavior: A Translational Approach Part 1 Neurobiology
Comai, S., Tau, M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f8770 · Cited by 130
Pharmacotherapy of aggression in children and adolescents: efficacy and effect size.
Pappadopulos, E. A., Woolston, S., Chait, A., Perkins, M. B., Connor, D. F., & Jensen, P. S. (2006) · PubMed · Cited by 171
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Wheeler, D. M., Silove, N., & Hazell, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub2 · Cited by 131
Posey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., Vitiello, B., Chuang, S. Z., Davies, M., Ramadan, Y., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.028 · Cited by 131
Self-citationZhou, M. S., Nasir, M., Farhat, L. C., Kook, M., Artukoglu, B. B., & Bloch, M. H. (2021) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.03.007 · Cited by 121
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“…complex agents such as risperidone (D 2 and 5-HT 2A/2C antagonist, etc.), which is effective for treatment of irritability in autism (McCracken et al, 2002; McPheeters et al, 2011), and buspirone (5-HT 1A partial agonist; D 2 , a 1 , a 2 antagonist, etc.), which is under study in a…”
BackgroundPsychopharmacological interventions in autism spectrum disorder
Accordino, R. E., Kidd, C., Politte, L. C., Henry, C. A., & McDougle, C. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154536 · Cited by 126
Self-citationPosey, D. J., Puntney, J. I., Sasher, T. M., Kem, D. L., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649084 · Cited by 127
Self-citationTian, J., Gao, X., & Yang, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.780407 · Cited by 145
“The autism diagnostic observation schedule, 2nd edition (ADOS-2) combined with ADI-R, has been regarded as the gold standard for assessing children with ASD (Lord et al., 2012; McCrimmon and Rostad, 2014).”
MethodAutism: A Review of the State of the Science for Pediatric Primary Health Care Clinicians
Barbaresi, W. J., Katusic, S. K., & Voigt, R. G. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.11.1167 · Cited by 126
“However, there is an evidence base for prescribing risperidone to assist in managing tantrums, aggression, and selfinjurious and stereotypic behaviors and for prescribing methylphenidate to manage inattentive, impulsive, and hyperactivebehaviors inchildrenwithautism.(117,118) Todate, there is insufficient evidence to…”
Background
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.